Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

83.30USD
12:09pm EDT
Change (% chg)

$-0.03 (-0.04%)
Prev Close
$83.33
Open
$83.34
Day's High
$83.70
Day's Low
$82.75
Volume
231,130
Avg. Vol
965,666
52-wk High
$86.71
52-wk Low
$64.25

Select another date:

Tue, Sep 12 2017

BRIEF-Eli Lilly updates on Jardiance tablets

* Jardiance® (Empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control

BRIEF-Eli Lilly to cuts jobs, focus on developing new medicines

* Lilly takes steps to streamline business, invest in new medicines and drive growth

BRIEF-Acrux says co and Eli Lilly and Co agreed to terminate licensing agreement for Axiron

* Acrux and Eli Lilly and Company have mutually agreed to terminate their licensing agreement for Axiron

BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement

* Nektar Therapeutics - Co, Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:

BRIEF-Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine

* Eli Lilly announces positive results for second phase 3 study of Lasmiditan for the acute treatment of Migraine

BRIEF-Lilly gets civil investigative demand from Minnesota AG for insulin product pricing‍​

* Says got civil investigative demand from Minnesota's office of Attorney General relating to pricing, sale of insulin products - SEC filing‍​

Lilly signals long delay for arthritis drug, shares fall

Eli Lilly and Co on Tuesday outlined a likely multi-year delay for its experimental rheumatoid arthritis drug with blockbuster sales potential, and disappointed investors sent its shares down nearly 4 percent.

BRIEF-Eli lilly says seeks external early cancer assets

* Eli Lilly says intends to be more active seeking external preclinical and early stage immuno-oncology assets

Drugmaker Lilly's profit jumps 35 percent

July 25 Eli Lilly and Co on Tuesday reported a 35 percent rise in quarterly profit as the U.S. drugmaker benefited from higher sales of its diabetes treatment Trulicity as well as its psoriasis drug Taltz.

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share

* Sets quarterly dividend of $0.52per share Source text for Eikon: Further company coverage:

Select another date: